Boehringer Starts Phase III Trial of Verducatib for COPD
Boehringer Ingelheim has registered a new Phase III clinical trial to evaluate verducatib, an experimental oral medicine for people living with chronic obstructive pulmonary disease…
Read More...
Read More...
